SNY: Japan Approves Wayrilz
Sanofi's Wayrilz is approved in Japan for persistent or chronic immune thrombocytopenia based on the LUNA 3 Phase 3 study
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results.
Sanofi's Wayrilz is approved in Japan for persistent or chronic immune thrombocytopenia based on the LUNA 3 Phase 3 study